This preprint is under consideration at European Journal of Hybrid Imaging. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Jun Zhao
Shanghai East Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0002-9887-5512
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: 68Ga-fibroblast activation protein specific enzyme inhibitor (FAPI) is a novel PET agent for tumor imaging.
Case description: We herein present a case where 68Ga-FAPI PET/MR helped to diagnose IgG4-RD that involved pancreas and bile duct. Our 62-year-old patient suffered from middle upper abdomen and brown urine. Blood test revealed abnormal liver function and elevated IgG4 (4.830g/L↑). 18F-FDG PET showed enlarged uncinate process and dilated bile duct tree. Mild increase of FDG uptake in uncinate process and head of pancreas indicated possible pancreatic malignancy, but the evidence was not sufficient enough. 68Ga-FAPI PET revealed prominent fibroblast mediated inflammation in the entire pancreas and bile duct, suggesting IgG4-RD.
Conclusion: The case illustrates that 68Ga-FAPI PET is more sensitive to IgG4-RD than 18F-FDG, and thus could be helpful in improving the differential diagnosis of pancreatitis and pancreatic cancer.
Keywords
68Ga-FAPI, PET/MR, pancreatitis, pancreatic cancer, IgG4-RD
Figure 1
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Revision
Version 1
Posted 09 Mar, 2021
No community comments so far
Review #2 received
Received 06 Apr, 2021
Editorial decision: Major revision
On 06 Apr, 2021
Review #1 received
Received 16 Mar, 2021
Reviewer #2 agreed
On 02 Mar, 2021
Review #? received
Received 02 Mar, 2021
Reviewers invited
Invitations sent on 02 Mar, 2021
Reviewer #1 agreed
On 02 Mar, 2021
Editor assigned
On 02 Mar, 2021
Submission checks complete
On 02 Mar, 2021
Editor invited
On 02 Mar, 2021
First submitted
On 02 Feb, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Nuclear Medicine & Medical Imaging
Learn more about our company.
This preprint is under consideration at European Journal of Hybrid Imaging. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Jun Zhao
Shanghai East Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0002-9887-5512
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Revision
Version 1
Posted 09 Mar, 2021
No community comments so far
Review #2 received
Received 06 Apr, 2021
Editorial decision: Major revision
On 06 Apr, 2021
Review #1 received
Received 16 Mar, 2021
Reviewer #2 agreed
On 02 Mar, 2021
Review #? received
Received 02 Mar, 2021
Reviewers invited
Invitations sent on 02 Mar, 2021
Reviewer #1 agreed
On 02 Mar, 2021
Editor assigned
On 02 Mar, 2021
Submission checks complete
On 02 Mar, 2021
Editor invited
On 02 Mar, 2021
First submitted
On 02 Feb, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Nuclear Medicine & Medical Imaging
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: 68Ga-fibroblast activation protein specific enzyme inhibitor (FAPI) is a novel PET agent for tumor imaging.
Case description: We herein present a case where 68Ga-FAPI PET/MR helped to diagnose IgG4-RD that involved pancreas and bile duct. Our 62-year-old patient suffered from middle upper abdomen and brown urine. Blood test revealed abnormal liver function and elevated IgG4 (4.830g/L↑). 18F-FDG PET showed enlarged uncinate process and dilated bile duct tree. Mild increase of FDG uptake in uncinate process and head of pancreas indicated possible pancreatic malignancy, but the evidence was not sufficient enough. 68Ga-FAPI PET revealed prominent fibroblast mediated inflammation in the entire pancreas and bile duct, suggesting IgG4-RD.
Conclusion: The case illustrates that 68Ga-FAPI PET is more sensitive to IgG4-RD than 18F-FDG, and thus could be helpful in improving the differential diagnosis of pancreatitis and pancreatic cancer.
Figure 1
Loading...